Edelweiss Mutual Fund has ended paused SIPs and STPs in six international schemes, while reopening its healthcare fund to new investments as India’s overseas allocation limits continue to constrain access.
Edelweiss Mutual Fund has drawn a sharper line under its overseas range, ending paused systematic investment plans in six international schemes while reopening one healthcare-focused fund to fresh money, according to notices issued on October 21.
The six schemes affected are the ASEAN, Greater China, US Technology, Emerging Markets Opportunities, Europe Dynamic and US Value funds. Investors who had been feeding those products through SIPs or systematic transfer plans will not have those arrangements automatically restored, and Edelweiss has not given a timetable for any restart. Existing holdings remain in place and investors can still redeem or switch out of them, but any new regular investment in those schemes will need to be set up again from scratch if the fund house ever reopens them.
The latest move follows months of interruptions tied to India’s overseas investment ceiling for mutual funds. Edelweiss first restricted fresh SIP and STP registrations in early July, after approaching the industry-wide limit that has been in force since February 2022. It later moved to suspend ongoing instalments as well, saying the restrictions would remain until more room became available under the overseas allocation framework.
The exception is Edelweiss’s MSCI India Domestic & World Healthcare 45 Index Fund, which will begin accepting new money again from October 26 and restart paused SIPs from November 20, subject to available headroom under the overseas cap. The fund tracks 45 healthcare companies and, as of September 30, held 54 per cent in Indian pharmaceutical and related businesses such as Sun Pharma and Divi’s Laboratories, 14 per cent in domestic hospital operators including Apollo and Max, and the remaining 31 per cent in 20 US-listed companies, most of them drug makers and medical technology firms. Over the past year it returned 13 per cent, with annualised gains of 19 per cent over three years and 14 per cent over five.
For investors, the practical message is less about a narrow product change than about how overseas exposure is now being rationed. Edelweiss’s healthcare fund is the only fresh entry point it has opened among the six schemes it had earlier frozen, and it offers a concentrated sector bet rather than broad global diversification. That makes the question for savers not simply whether they can keep investing abroad, but whether the new route still fits the purpose of the original SIP.
The shift also comes as premiums in exchange-traded funds linked to foreign markets have eased, though they remain elevated in some cases. Over the week to October 21, premiums fell across all four ETFs holding US shares, while those tied to Hong Kong stocks moved higher, according to Value Research. The Motilal Oswal Nasdaq Q50 ETF saw the sharpest adjustment, with its premium slipping from 112 per cent to 91 per cent as trading volumes cooled. Even after that decline, it still trades at a steep premium to the value of its underlying holdings, a reminder that buying overseas exposure through an ETF can be costly when demand outruns supply.
For anyone whose SIP has been cancelled, the immediate task is to decide where that money should go next rather than waiting for a restoration that may never come. And for investors considering foreign exposure, the broader lesson is that access can change quickly when regulatory limits tighten, leaving fund houses to reshuffle the available routes abroad.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
